<DOC>
	<DOCNO>NCT01956305</DOCNO>
	<brief_summary>DS-7309 develop treatment type 2 diabetes mellitus ( T2DM ) . This randomized , placebo-controlled , blind , sequential , multiple ascend dose study assess safety , tolerability , Pharmacokinetics ( PK ) , Pharmacodynamics ( PD ) multiple dose DS-7309 subject T2DM .</brief_summary>
	<brief_title>Randomized , Placebo-controlled , 2 Period , Single-blind , Sequential , Multiple Ascending Dose Study</brief_title>
	<detailed_description>DS-7309 develop treatment type 2 diabetes mellitus ( T2DM ) . This randomized , placebo-controlled , single-blind ( subject investigator-blinded , sponsor-unblinded ) , sequential , multiple ascend dose study assess safety , tolerability , Pharmacokinetic ( PK ) , Pharmacodynamic ( PD ) multiple dose DS-7309 subject T2DM . The safety tolerability new dose level test single day administration prior start repeat dosing .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female volunteer age 18 65 year , inclusive . Male subject agree contraception ( condom spermicide ) addition female partner ( childbearing potential ) use another form contraception Women must nonchildbearing potential Diagnosed T2DM least 3 month prior first dose . Subjects must either : On monotherapy either metformin DPPIV inhibitor alone HbA1c 6.5 % 9.5 % , inclusive , willing discontinue current metformin DPPIV inhibitor treatment least 2 week prior check discharge clinic ( Cohorts A E ) . OR Treatment naive antidiabetes mellitus drug least 3 month prior Screening HbA1c 7 % 10 % , inclusive . Fasting plasma glucose ≥100 mg/dL ≤250 mg/dL Screening . Fasting plasma glucose ≥120 mg/dL ≤250 mg/dL Day 6 . All woman must negative serum pregnancy test Screening within 2 day dose . A BMI 19 36 kg/m2 inclusive ; , outside range , clinically significant agree upon DSPD CRO Investigator . Good health determine absence clinically significant deviation normal , base medical history , physical examination , laboratory report , triplicate 12lead ECG ( except finding associate T2DM ) , deem Investigator , prior enrollment . Has give write informed consent prior participate study . Able understand willing comply study requirement , willing allow collection blood urine specimen . Negative urine test drug abuse ( opiate , benzodiazepine , amphetamine , cannabinoids , cocaine , barbiturate , phencyclidine ) , cotinine , alcohol Screening . Negative result HIV antibody hepatitis B surface antigen , hepatitis C antibody Screening . Willing abstain grapefruit/grapefruit juice Seville oranges 10 day first dose throughout study . Willing refrain consume food beverage contain caffeine/xanthine start 24 hour prior checkin . History type 1 diabetes and/or history diabetic ketoacidosis . History clinical laboratory evidence significant complication T2DM , include proliferative retinopathy , macroalbuminuria , peripheral neuropathy , ischemic heart disease , stroke , peripheral vascular disease . Screening laboratory value outside range normal value deem clinically significant Investigator . Liver function test ( AST , ALT , total bilirubin ) lactate dehydrogenase must 1.5 time ULN . If subject nonclinically significant high abnormal read 1 liver function test result 1.5 time ULN repeat test , subject may enrol provide result laboratory test perform day checkin also 1.5 time ULN . Estimated glomerular filtration rate ( eGFR ) &lt; 80 mL/min . Any history drug abuse . History alcohol addiction 2 year prior Screening . History significant allergic response drug except penicillin . History current evidence , determine Investigator , psychiatric emotional problem would invalidate give informed consent limit ability subject comply study requirement . History current evidence clinically significant cardiac , hepatic , renal , urinary , pulmonary , endocrine , neurologic , infectious , gastrointestinal , hematologic , oncologic disease determine Investigator . Subjects history congenital long QT syndrome , history survive neardrowning episode , history unexplained syncope loss consciousness . Subjects QTcF interval duration &gt; 450 msec obtain average ECG machine reading triplicate ECG take Screening . Subjects abnormal ECG waveform morphology ECGs screening triplicate would preclude accurate manual measurement QT interval duration . Hemoglobin &lt; 12.0 g/dL Screening . Need concomitant medication except specify Consumption food beverage contain alcohol 24 hour checkin discharge clinic . Blood donation 500 mL significant blood loss within 56 day checkin . Plasma donation within 7 day checkin . Participation another investigational new drug research study within 30 day checkin . Use tobacco product nicotinecontaining product ( include smoke cessation aid , gum patch ) within 6 month checkin . Relationship subject Investigator , subInvestigator , pharmacist , study coordinator , staff directly involve conduct study , employment DSPD CRO participate study . Familial relationship subject subject previously currently enrol study . Enrollment prior dose cohort study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2014</verification_date>
</DOC>